Quick answer
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2, about 712 Da) that acts as an agonist at the ghrelin/growth hormone secretagogue receptor GHS-R1a. In the original rat and swine characterization it released growth hormone at levels comparable to GHRP-6 while leaving ACTH and cortisol close to baseline, which is why it is described as a selective secretagogue and used as a probe of one signaling pathway. For laboratory research use only; not for human consumption.
- Class: growth-hormone secretagogue; ghrelin-receptor agonist, not a GHRH analog
- Signaling: Gq, phospholipase C, intracellular calcium mobilization
- Defining property: growth-hormone release in model systems with little accompanying ACTH, cortisol or prolactin response
- Bench math: mg in vial ÷ mL diluent = mg/mL; use the reconstitution calculator
Ipamorelin is one of the most frequently cited reference compounds in growth-hormone-axis research. It is short, chemically well defined and, within the limits of the available model systems, unusually clean in its pharmacology. This guide brings together what is known about its identity, history, structure, mechanism and preclinical behavior, then covers laboratory handling and quality documentation. It is research education, not usage guidance. For laboratory research use only; not for human consumption.
What it is
Ipamorelin is a five-residue synthetic peptide classified as a growth-hormone secretagogue. It is widely used as a selective probe of the ghrelin/GHS receptor because it stimulates growth-hormone release with comparatively little effect on other pituitary hormones in model systems. That makes it a useful tool for attributing an observed effect specifically to GHS-receptor activation rather than to a mixture of endocrine signals.
Two features set it apart from the GHRH-analog class. First, it acts at a different receptor. Second, its pharmacology is calcium-linked rather than cAMP-linked, so it complements, and does not duplicate, releasing-hormone analogs such as sermorelin and CJC-1295 (no DAC). The laboratory material is listed as Ipamorelin 10 mg research vials.
Where it fits among secretagogues
Compared with earlier, more potent but less specific growth-hormone-releasing peptides, ipamorelin is valued for a narrower response profile, which positions it as a benchmark selective secretagogue. It does not reproduce the full biology of endogenous ghrelin, which is a larger acylated peptide with broader physiological context. The distinction matters whenever a result is described as “ghrelin-like”: ipamorelin is a defined synthetic agonist of one receptor, nothing more.
Discovery and history
Ipamorelin emerged from the search for growth-hormone-releasing peptides with cleaner selectivity than earlier secretagogues. The first GHRPs, described in the early 1980s, demonstrated that short synthetic sequences could stimulate the pituitary through a receptor distinct from the GHRH receptor (Bowers et al., 1984). Potent follow-ons such as hexarelin were effective, but they often also influenced cortisol and prolactin, which complicated interpretation. Researchers therefore pursued analogs that engaged the same receptor class with fewer off-target endocrine signals.
A selectivity milestone
Raun and colleagues (1998) characterized ipamorelin as a pentapeptide secretagogue with selectivity as its headline property. Working in rat pituitary cell cultures and in rat and swine models, they reported growth-hormone release comparable to GHRP-6 while ACTH and cortisol stayed near baseline, even at concentrations far above those needed for a maximal growth-hormone response. That clean profile is what earned the molecule lasting attention as a reference compound.
The ghrelin receptor catches up
The receptor that GHRPs act through was cloned in 1996 (Howard et al.), and ghrelin was identified as its endogenous ligand in 1999 (Kojima et al.). That sequence of discoveries gave context to how ipamorelin works: it and its GHRP relatives act through a natural signaling system and are not artificial interlopers. After this, the pentapeptide became a compact synthetic probe for separating receptor-mediated effects from those of GHRH analogs.
A reference probe, not a new pathway
The historical value of ipamorelin lies in refining a known synthetic-ligand class, not in establishing a new endocrine pathway. Candidate secretagogues could be compared across receptor activity, growth-hormone readouts and unrelated pituitary signals, allowing selectivity to become an explicit design criterion. It is best understood as a product of iterative medicinal chemistry and comparative pharmacology, not as a fragment isolated from a natural hormone. Its pairing with GHRH analogs is a common design in combination research; see CJC-1295 and ipamorelin: discovery and history and the ipamorelin discovery article.
Chemical structure and synthesis
The sequence is conventionally written Aib-His-D-2-Nal-D-Phe-Lys-NH2: five residues terminating in a C-terminal amide. Rather than being derived from a natural protein, it was engineered position by position to optimize binding to the ghrelin/GHS receptor. How non-standard residues fit into an ordered chain is covered in understanding amino acid sequences.
| Position | Residue | Structural role |
|---|---|---|
| 1 | Aib (2-aminoisobutyric acid) | Constrains backbone conformation; resists enzymatic cleavage |
| 2 | His | Standard residue; imidazole side chain |
| 3 | D-2-Nal (D-2-naphthylalanine) | Bulky aromatic D-residue; sharpens receptor selectivity and stability; adds hydrophobicity |
| 4 | D-Phe | D-configured aromatic residue; protease resistance |
| 5 | Lys-NH2 | Basic residue with C-terminal amide cap |
Why the non-natural residues matter
Several building blocks are absent from ordinary proteins. Aib constrains the backbone and resists enzymatic cleavage, while the D-configured and naphthylalanine residues sharpen receptor selectivity and stability. These deliberate substitutions are the structural reason ipamorelin behaves cleanly at its target. Capping the chain with an amide instead of a free carboxyl removes a negative charge and further improves resistance to carboxypeptidases, a small but meaningful contribution to the stability profile.
Synthesis and finishing
The short length makes solid-phase peptide synthesis efficient and high-yielding. The peptide is assembled on resin, cleaved, purified by preparative chromatography and lyophilized (see what is lyophilization) into a stable powder for shipping and storage. Manufacturing a short sequence is nonetheless not automatically trivial. Each D-residue and nonstandard aromatic building block must carry the correct stereochemistry, and side-chain protecting groups must survive repeated coupling cycles before clean removal at final cleavage. Incomplete coupling can create deletion sequences whose masses differ only modestly from the target, while racemization can yield an isomer with the same elemental composition but altered receptor behavior.
Purity and identity are read out by HPLC and mass spectrometry, the latter confirming the expected molecular weight including the non-natural residues. Because biological selectivity depends on exact residue identity and configuration, process controls monitor coupling completion and final characterization goes beyond nominal peptide content. Further detail is in ipamorelin structure and synthesis.
Mechanism of action
The proposed mechanism is agonism at GHS-R1a, the receptor targeted by ghrelin. As a synthetic pentapeptide, ipamorelin mimics ghrelin’s activating action at this receptor, while its engineered residues confine its activity largely to this single target.
Receptor engagement and signaling
Binding to GHS-R1a activates Gq-coupled signaling, which stimulates phospholipase C and mobilizes intracellular calcium in pituitary somatotrophs, promoting growth-hormone release in model systems. This pathway is mechanistically distinct from the cAMP-driven route used by GHRH analogs (see sermorelin mechanism), which is why the two receptor classes are so often studied side by side.
| Feature | Ipamorelin (GHS-R1a agonist) | GHRH analogs (e.g. sermorelin, CJC-1295 no DAC) |
|---|---|---|
| Receptor | GHS-R1a (ghrelin receptor) | GHRH receptor |
| Principal second messenger | Calcium, via Gq and phospholipase C | cAMP |
| Structural class | Synthetic pentapeptide with non-natural residues | GHRH-fragment or GHRH-derived sequences |
| Reported secondary pituitary effects | Limited cortisol and prolactin response in models | Not the same selectivity question |
Selectivity as a research feature
In preclinical models ipamorelin shows limited effect on cortisol and prolactin, in contrast with older, less specific secretagogues such as hexarelin. This lets researchers attribute observed effects to GHS-R signaling with greater confidence. Selectivity should nonetheless be tested and not assumed: comparatively limited cortisol or prolactin responses in one model do not guarantee absence of every off-target interaction in another.
Complementarity with GHRH signaling
Ghrelin-receptor and GHRH-receptor pathways converge on the same somatotroph cells through different second messengers. In pituitary cell preparations the GHRH pathway raises cAMP while the ghrelin-receptor pathway mobilizes calcium, and the combined stimulus is often reported to exceed either alone. This mechanistic complementarity underlies much of the interest in pairing ipamorelin with GHRH analogs, as examined in the CJC-1295 and ipamorelin mechanism article.
Receptor context and assay dependence
GHS-R1a has notable constitutive activity and can produce different downstream patterns depending on receptor density, cellular background and assay timing. A calcium-flux assay, a second-messenger assay and a pituitary hormone-release model therefore measure related but non-identical parts of ipamorelin pharmacology. Receptor antagonists, GHS-R-negative controls and concentration-response designs help establish that a signal is receptor dependent. Replicates should report the response window and baseline receptor activity, since both change the apparent magnitude and shape of agonist signaling.
Preclinical research findings
Preclinical work on ipamorelin is built around the theme of specificity: how cleanly a secretagogue triggers growth-hormone release with minimal engagement of unrelated signaling such as cortisol and prolactin pathways. The molecule became a reference in this discussion because it consistently showed a narrow response profile.
| Model or system | Endpoint | Finding or use |
|---|---|---|
| Rat pituitary cell cultures | Growth-hormone release | Growth-hormone release comparable to GHRP-6 (Raun et al., 1998) |
| Rat models | Growth hormone versus ACTH and cortisol | ACTH and cortisol stayed near baseline, even at concentrations far above those needed for a maximal growth-hormone response |
| Swine models | Growth-hormone release | Release reported alongside the selectivity profile described in the original characterization |
| Receptor-expressing cell lines | Calcium flux through GHS-R1a | Used to isolate GHS-R-driven signaling from GHRH-driven signaling |
| Combination designs with GHRH analogs | Additive versus interactive growth-hormone readouts | Two distinct receptor inputs studied together for pathway interaction |
Receptor-pathway experiments
Because its target is the ghrelin/GHS receptor, ipamorelin is used to isolate GHS-R-driven signaling from GHRH-driven signaling. This makes it a clean probe for dissecting which pituitary responses depend on the secretagogue pathway versus the releasing-hormone pathway in controlled systems. Partners in combination work include CJC-1295 (no DAC), with its own preclinical overview, and related secretagogues such as hexarelin serve as potency comparators.
Endpoints and comparison standards
Useful experiments pair a proximal endpoint, such as receptor-dependent calcium mobilization, with a downstream endpoint such as growth-hormone release from an appropriate model. Including ghrelin or a well-characterized GHRP as a comparator helps distinguish potency from selectivity, while a GHRH analog serves as a pathway control and not as a same-receptor control. Time-matched vehicle groups and receptor-blocking conditions strengthen causal interpretation. Measuring more than one hormone-related endpoint also tests the claimed selectivity directly instead of inferring it from growth-hormone release alone.
Reproducibility and scope
Peptide adsorption, proteolysis and repeated freeze–thaw exposure can lower the active concentration, so analytical integrity and handling records belong in the experimental design. These observations arise from controlled models and describe research behavior, not application. See also the ipamorelin preclinical research article.
Handling, reconstitution and storage
The unnatural residues give ipamorelin strong resistance to enzymatic breakdown. The naphthylalanine makes it somewhat more hydrophobic than a typical pentapeptide, but it still dissolves readily in bacteriostatic water with gentle swirling. The general technique is the same as for any lyophilized peptide: allow the vial to reach room temperature before opening, use sterile technique, and add bacteriostatic water slowly down the inside wall of the vial rather than onto the cake. Dissolve by swirling; do not vortex or shake. The full procedure is in the lyophilized-peptide reconstitution guide, and the compound-specific notes are in ipamorelin reconstitution and storage.
Concentration math
Concentration (mg/mL) equals the mass in the vial divided by the diluent volume. The table shows a 10 mg vial; molarity assumes 712 Da and 100% peptide content, so correct with certificate data for exact work. The reconstitution calculator handles other vial sizes, and the calculator guide explains the arithmetic.
| Mass in vial | Diluent added | Concentration | Approx. molarity |
|---|---|---|---|
| 10 mg | 1 mL | 10 mg/mL | about 14.0 mM |
| 10 mg | 2 mL | 5 mg/mL | about 7.0 mM |
| 10 mg | 3 mL | 3.33 mg/mL | about 4.7 mM |
| 10 mg | 5 mL | 2 mg/mL | about 2.8 mM |
Prepare working dilutions fresh, since dilute peptide solutions lose material to container surfaces and to slow chemical degradation.
Storage
Lyophilized ipamorelin is quite stable and should be kept cold, dry and away from light. After reconstitution the main controllable factor is temperature, and aliquoted storage is the standard way to avoid repeated cycling. The storing research peptides overview covers general cold-chain principles. A fully worked bench protocol with concentration tables for another peptide is in how to reconstitute retatrutide step by step; the technique transfers directly, with only the masses and molecular weight changing. If the study uses the pre-mixed secretagogue pair, the matching handling notes are in CJC-1295 and ipamorelin reconstitution and storage.
Purity, COA and quality
Reagent problems are far cheaper to catch before an assay than after it. For ipamorelin, a useful certificate of analysis reports chromatographic purity with the trace and a mass-spectrometry identity consistent with about 712 Da. Because stereochemistry matters here, remember that a D-to-L change would not alter the measured mass; a chromatographic method able to resolve closely related species is therefore more informative than purity percentage alone.
| Check | What to confirm |
|---|---|
| Batch match | The CoA batch number is the same as the vial label |
| HPLC purity | Reported value with the actual chromatogram, not just a number |
| Mass identity | Observed mass agrees with the theoretical value of about 712 Da |
| Storage history | Vial arrived sealed and has been kept cold, dry and dark since receipt |
Noting the batch number alongside each dataset lets lot-to-lot differences be identified later instead of being mistaken for biological variability. Read documents using how to read a COA and understanding HPLC purity; batch documents are on the CoA page, and compound specifics are in ipamorelin purity testing. For sourcing criteria see where to buy ipamorelin for research; the catalog entry is the ipamorelin product page.
Related compounds and comparisons
Ipamorelin is most often discussed against three neighbors. Hexarelin is the more potent but less selective GHRP. Sermorelin is a GHRH-fragment analog acting at a different receptor, and the contrast illustrates why the two classes are studied together. CJC-1295 is a longer-acting GHRH analog commonly paired with it, and the pre-mixed option is the CJC-1295 (No DAC) + Ipamorelin blend, explained in the blend article. Downstream of the growth-hormone axis, the engineered growth factor IGF-1 LR3 is used to examine IGF-1 receptor signaling. A short-answer companion is the ipamorelin research FAQ.
Frequently asked questions
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, with a theoretical average mass of about 712 Da. It is classified as a growth-hormone secretagogue and acts as an agonist at the growth hormone secretagogue receptor GHS-R1a, the receptor activated by ghrelin.
What makes ipamorelin “selective”?
In the original characterization (Raun et al., 1998), ipamorelin released growth hormone in rat pituitary cell cultures and in rat and swine models at a level comparable to GHRP-6, while ACTH and cortisol stayed near baseline even at concentrations far above those needed for a maximal growth-hormone response. That separation between growth-hormone release and other pituitary outputs is what the term refers to.
Is ipamorelin a fragment of ghrelin?
No. It is a fully synthetic pentapeptide developed from the growth-hormone-releasing peptide (GHRP) series. It shares no sequence with ghrelin even though both activate the same receptor.
Which receptor does ipamorelin act on, and what is the signaling route?
GHS-R1a, a G-protein-coupled receptor. Activation signals through Gq, stimulating phospholipase C and mobilizing intracellular calcium in pituitary somatotrophs. This is mechanistically distinct from the cAMP-driven route used by GHRH analogs. See the mechanism of action article.
Why is ipamorelin often paired with a GHRH analog in research?
The two act on separate receptors that converge on the same somatotroph cells through different second messengers, cAMP for the GHRH receptor and calcium for GHS-R1a. Researchers study whether combined input is additive or interactive. See CJC-1295 and ipamorelin in growth hormone research and the CJC-1295 vs ipamorelin comparison.
How does ipamorelin compare with hexarelin as a research tool?
Hexarelin is reported as more potent but less selective, with greater cortisol and prolactin co-release in model systems. Ipamorelin is valued for its narrower response profile. The full side-by-side is in the hexarelin vs ipamorelin research comparison.
How is lyophilized ipamorelin stored?
As a lyophilized powder it is quite stable when kept cold, dry and protected from light. After reconstitution, temperature is the main controllable factor, and single-use aliquots avoid repeated freeze–thaw cycling. See ipamorelin reconstitution and storage.
How do I work out a stock concentration?
Divide the mass in the vial by the volume of diluent added. A 10 mg vial reconstituted with 2 mL gives 5 mg/mL, which is about 7.0 mM at 712 Da. The peptide calculator does this for any combination.
What documentation verifies a research-grade lot?
A lot-specific certificate of analysis reporting HPLC purity and mass-spectrometry identity, ideally with raw traces and a batch number matching the vial. Published documents are on the CoA page, and specific impurities and expected mass values are discussed in ipamorelin purity testing.
For laboratory research use only; not for human consumption. Material is supplied for in-vitro and analytical work only. Product page: Ipamorelin research vials.
References
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
- Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545.
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660.